The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

2.

CAR-T cell therapy for cancer causes 'brain fog,' study shows

3.

Squeezing through tiny blood vessels may trigger melanoma cells to spread

4.

Fear of hair loss might cause some to reject cancer treatment

5.

Q&A: Why adolescents and young adults with cancer are falling behind


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot